Regorafenib‐induced hand–foot skin reaction with striking epidermal dysmaturation – a new histopathological pattern associated with the use of multi‐kinase inhibitors

2016 ◽  
Vol 175 (1) ◽  
pp. 216-217 ◽  
Author(s):  
M. Llamas‐Velasco ◽  
I. Hegyi ◽  
U. Hesterberg ◽  
E. Daudén ◽  
L. Requena ◽  
...  
Keyword(s):  
Skin Reaction ◽  
Kinase Inhibitors ◽  
Hand Foot Skin Reaction

scholarly journals The Efficacy and Safety of the Shouzu Ning Decoction Treatment for Multi-Kinase Inhibitors-Associated Severe Hand–Foot Skin Reaction

2021 ◽  
Vol Volume 13 ◽  
pp. 45-53
Author(s):  
Liumei Shou ◽  
Tianyu Shao ◽  
Fangmin Zhao ◽  
Shuyi Chen ◽  
Qunwei Chen ◽  
...  
Keyword(s):  
Skin Reaction ◽  
Kinase Inhibitors ◽  
Efficacy And Safety ◽  
Hand Foot Skin Reaction

Evolving Strategies for the Management of Hand–Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib

2008 ◽  
Vol 13 (9) ◽  
pp. 1001-1011 ◽  
Author(s):  
Mario E. Lacouture ◽  
Shenhong Wu ◽  
Caroline Robert ◽  
Michael B. Atkins ◽  
Heidi H. Kong ◽  
...  
Keyword(s):  
Skin Reaction ◽  
Kinase Inhibitors ◽  
Hand Foot Skin Reaction

Toxicities of axitinib, sunitinib and temsirolimus: implications for progression-free and overall survival in metastatic renal cell cancer

2020 ◽  
Author(s):  
Annemarie Uhlig ◽  
Johannes Uhlig ◽  
Lutz Trojan ◽  
Michael Woike ◽  
Marianne Leitsmann ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cancer Patients ◽  
Skin Reaction ◽  
Renal Cell Cancer ◽  
Renal Cell ◽  
Cell Cancer ◽  
Progression Free Survival ◽  
Cox Models ◽  
Metastatic Renal Cell Cancer ◽  
Hand Foot Skin Reaction

The aim of this study was to evaluate the association between axitinib, sunitinib and temsirolimus toxicities and patient survival in metastatic renal cell cancer patients. Overall survival (OS) and progression-free survival (PFS) of metastatic renal cell cancer patients from the prospective multicenter STAR-TOR study were assessed using multivariable Cox models. A total of 1195 patients were included (n = 149 axitinib; n = 546 sunitinib; n = 500 temsirolimus). The following toxicities significantly predicted outcomes: hand–foot skin reaction (hazard ratio [HR] = 0.29) for PFS with axitinib; stomatitis (HR = 0.62) and pneumonitis (HR = 0.23) for PFS with temsirolimus; stomatitis (HR = 0.52) and thrombocytopenia (HR = 0.6) for OS with temsirolimus; fatigue (HR = 0.71) for PFS with sunitinib; hand–foot skin reaction (HR = 0.56) and fatigue (HR = 0.58) for OS with sunitinib. In conclusion, in metastatic renal cell cancer, axitinib, sunitinib and temsirolimus demonstrate specific toxicities that are protective OS/PFS predictors.

scholarly journals Grade III hand-foot skin reaction induced by sorafenib

2017 ◽  
Vol 92 (4) ◽  
pp. 590-591 ◽  
Author(s):  
Anca Chiriac ◽  
Marius Florin Coros ◽  
Cristian Podoleanu ◽  
Simona Stolnicu
Keyword(s):  
Skin Reaction ◽  
Hand Foot Skin Reaction ◽  
Grade Iii

scholarly journals Safety and Efficacy of Bis-Glyceryl Ascorbate (Amitose DGA) to Prevent Hand-Foot Skin Reaction in Patients With Renal Cell Carcinoma Receiving Sunitinib Therapy: Protocol for a Phase I/II, Uncontrolled, Single-Arm, Open-Label Trial (Preprint)

2019 ◽  
Author(s):  
Kazuhiro Yamamoto ◽  
Takeshi Ioroi ◽  
Kenichi Harada ◽  
Satoshi Nishiyama ◽  
Chikako Nishigori ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Ascorbic Acid ◽  
Phase I ◽  
Cell Carcinoma ◽  
Skin Reaction ◽  
Renal Cell ◽  
Single Center ◽  
Open Label ◽  
Open Label Trial ◽  
Hand Foot Skin Reaction

BACKGROUND Hand-foot skin reaction (HFSR) is a serious side effect induced by multiple-tyrosine kinase inhibitors (TKIs). HFSR can cause treatment interruption or decreased dosing. HFSR also markedly decreases quality of life and is associated with the therapeutic efficacy of multiple-TKIs. Therefore, the management and prevention of HFSR is an important issue; however, an effective method for its prevention has not been established. Specific ascorbic acid derivatives can reverse multiple-TKI-induced keratinocyte growth and pathological changes in vitro. OBJECTIVE This study was designed to evaluate the safety of bis-glyceryl ascorbate (Amitose DGA), a novel, hydrosoluble, and moisturizing ascorbic acid derivative, in patients with renal cell carcinoma (RCC) receiving sunitinib therapy. This study was also designed to evaluate Amitose DGA’s preventive efficacy for sunitinib-induced HFSR. METHODS This is a Phase I/II, single-center, uncontrolled, single-arm, open-label trial. We will recruit a total of 30 patients with RCC receiving sunitinib therapy, with a 2-week-on and 1-week-off schedule. The participants will apply Amitose DGA-containing cream over both palmar and plantar surfaces within two treatment cycles (ie, 6 weeks) of sunitinib in combination with a general moisturizing agent, in addition to standard-of-care processes. Safety assessments will include dermatological abnormalities, clinical laboratory tests, and incidence of adverse events. Efficacy assessments will include development of HFSR and therapeutic outcomes associated with sunitinib. RESULTS Recruitment to the study began in August 2017 and is ongoing in Japan. To date, 21 subjects have been recruited. Study completion is expected in 2021. CONCLUSIONS This is the first clinical study of Amitose DGA-containing cream in patients with RCC who are receiving sunitinib therapy. The single-center, single-arm, open-label design was selected to maximize subject exposure and increase the likelihood of achieving our study endpoints. The results will provide valuable and preliminary evidence of the effects of Amitose DGA-containing cream on HFSR. CLINICALTRIAL UMIN Clinical Trials Registry UMIN000027209; https://upload.umin.ac.jp/cgi-open-bin/ctr /ctr_view.cgi?recptno=R000031174 INTERNATIONAL REGISTERED REPOR DERR1-10.2196/14636

Sign in / Sign up

Export Citation Format

Share Document